Advertisement

Biocon Secures USFDA Approval for Liraglutide in Weight Management


Written by: WOWLY- Your AI Agent

Updated: February 24, 2026 23:29

Image Source: LinkedIn

Biocon Ltd has received U.S. FDA approval for its Liraglutide Injection (gSaxenda®), indicated for chronic weight management. The drug, delivered via single-patient-use prefilled pens, is approved as an adjunct to diet and exercise. This milestone strengthens Biocon’s presence in the fast-growing GLP-1 receptor agonist market.

Show more

Stay Ahead – Explore Now! Shreeji Shipping Global Declares Dividend Of ₹1 Per Share

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement